Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD5 | P21918 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1331130 | 1.00 | EPHX1 (0.33) | EPHX1DRD2DRD1DRD4DRD5 | |
| SCHEMBL318567 | 1.00 | EPHX1 (0.33) | EPHX1DRD2DRD1DRD4DRD5 | |
| SCHEMBL318765 | 1.00 | EPHX1 (0.33) | EPHX1DRD2DRD1DRD4DRD5 | |
| SCHEMBL514446 | 1.00 | EPHX1 (0.33) | EPHX1DRD2DRD1DRD4DRD5 | |
| SCHEMBL318176 | 1.00 | EPHX1 (0.33) | EPHX1DRD2DRD1DRD4DRD5 | |
| SCHEMBL3615951 | 0.99 | EPHX1 (0.31) | EPHX1DRD2DRD1DRD4DRD5 | |
| SCHEMBL305737 | 0.94 | DRD2 (0.31) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL318426 | 0.90 | EPHX1 (0.34) | EPHX1DRD2DRD1DRD4DRD5 | |
| SCHEMBL319659 | 0.88 | DRD2 (0.34) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL1736116 | 0.87 | EPHX1 (0.31) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118156589-A | Composition, ceramic electrolyte film, preparation method, composite film and application | 深圳欣界能源科技有限公司 | 2024-06-07 | — | — | CN | claimed |
| US-20250041239-A1 | ORALLY DISSOLVING ANTIMICROBIAL FILM COMPOSITIONS & METHODS OF THEIR USE | ISHA Therapeutics LLC (US) | 2025-02-06 | — | — | US | disclosed |
| US-12109303-B2 | Orally dissolving antimicrobial film compositions and methods of their use | ISHA Therapeutics LLC (US) | 2024-10-08 | — | — | US | disclosed |
| CN-118156589-A | Composition, ceramic electrolyte film, preparation method, composite film and application | 深圳欣界能源科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20230330012-A1 | ORALLY DISSOLVING ANTIMICROBIAL FILM COMPOSITIONS & METHODS OF THEIR USE | ISHA Therapeutics LLC | 2023-10-19 | — | — | US | disclosed |
| US-11623971-B2 | Freestanding ion gel and method for preparing the same | Research & Business Foundation Sungkyunkwan University (KR) | 2023-04-11 | — | — | US | disclosed |
| US-20210054127-A1 | FREESTANDING ION GEL AND METHOD FOR PREPARING THE SAME | Research & Business Foundation Sungkyunkwan University (KR) | 2021-02-25 | — | — | US | disclosed |
| EP-3080859-B1 | NA BASED SECONDARY BATTERY | FIELD UPGRADING USA (US) | 2020-04-08 | — | — | EP | disclosed |
| CN-104617338-B | Sodium rechargeable battery comprising forming slotted graphite felt | SK新技术株式会社 | 2019-11-12 | — | — | CN | disclosed |
| CN-104600352-B | Sodium rechargeable battery with the graphite felt for forming air vent channel | SK INNOVATION CO.,LTD. (KR) | 2019-11-01 | — | — | CN | disclosed |
| US-20100188732-A1 | MULTICOLOR DISPLAY OPTICAL COMPOSITION, OPTICAL DEVICE, AND DISPLAY METHOD OF OPTICAL DEVICE | FUJI XEROX CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-7746542-B2 | Multicolor display optical composition, optical device, and display method of optical device | FUJI XEROX CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090291872-A1 | Ionic Liquids and Methods For Using the Same | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291874-A1 | IONIC LIQUIDS AND METHODS FOR USING THE SAME | UNITED STATES GOVERNMENT; DEFENSE THREAT REDUCTION AGENCY | 2009-11-26 | — | — | US | disclosed |
| US-7455903-B2 | Optical materials and optical elements using the same | FUJI XEROX CO., LTD. (JP) | 2008-11-25 | — | — | US | disclosed |
| US-20070121193-A1 | Multicolor display optical composition, optical device, and display method of optical device | FUJI XEROX CO., LTD. | 2007-05-31 | — | — | US | disclosed |
| US-20060121285-A1 | Optical materials and optical elements using the same | FUJI XEROX CO., LTD. | 2006-06-08 | — | — | US | disclosed |
| US-7009077-B2 | Aromatic sulfonation reactions | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2006-03-07 | — | — | US | disclosed |
| EP-1324982-B1 | AROMATIC SULFONATION REACTIONS | UNIV BELFAST (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20040242932-A1 | Aromatic sulfonation reactions | QUEEN'S UNIVERSITY OF BELFAST, THE (GB) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242932-A1 | Aromatic sulfonation reactions | ARSA, TYR, TST | EPHX1 2577/4885DRD2 2612/4885DRD1 1819/4885 |
| US-20090291872-A1 | Ionic Liquids and Methods For Using the Same | INMT, ICMT, ABL1 | EPHX1 2034/4885DRD2 1338/4885DRD1 2636/4885 |
| US-20250041239-A1 | ORALLY DISSOLVING ANTIMICROBIAL FILM COMPOSITIONS & METHODS OF THEIR USE | RAB5IF, CGAS, APOB | EPHX1 4354/4885DRD2 2231/4885DRD1 2845/4885 |
| US-20230330012-A1 | ORALLY DISSOLVING ANTIMICROBIAL FILM COMPOSITIONS & METHODS OF THEIR USE | RAB5IF, CGAS, APOB | EPHX1 4354/4885DRD2 2231/4885DRD1 2845/4885 |
| US-12109303-B2 | Orally dissolving antimicrobial film compositions and methods of their use | RAB5IF, APOB, ERG28 | EPHX1 4186/4885DRD2 1945/4885DRD1 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.